+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Human Microbiome Market - Global Forecast 2026-2032- Product Image
Human Microbiome Market - Global Forecast 2026-2032- Product Image
Sale

Human Microbiome Market - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4857894
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Human Microbiome Market is projected to reach USD 2.98 Billion in 2026. It is expected to continue growing at a CAGR of 24.83%, reaching USD 11.40 Billion by 2032.

The human microbiome has moved from exploratory sequencing into evidence-based healthcare, linking microbial communities across the gut, skin, oral cavity, urogenital tract, and respiratory system with immunity, metabolism, inflammation, neurological signaling, and drug response. Advances in shotgun metagenomics, metabolomics, multi-omics integration, and strain-level profiling are improving the ability to identify clinically relevant microbial functions rather than relying only on taxonomic associations.

For industry leaders, the highest-value opportunities are concentrated in microbiome therapeutics, live biotherapeutic products, companion diagnostics, metagenomic testing, probiotics, prebiotics, synbiotics, postbiotics, and precision nutrition. Regulatory milestones, including FDA-approved microbiota-based products for recurrent Clostridioides difficile infection, validate the field’s clinical direction and reinforce the need for robust safety, manufacturing, and efficacy evidence.

Transformative Shifts in the Human Microbiome Landscape

The landscape is shifting from broad probiotic positioning to mechanism-led interventions supported by metagenomics, metabolomics, strain-level analytics, standardized endpoints, and controlled clinical evidence. Companies are increasingly prioritizing defined consortia, postbiotics, next-generation probiotics, microbiome biomarkers, and targeted live biotherapeutic products over generalized wellness claims.

Another transformative shift is the convergence of microbiome science with oncology, immunology, gastroenterology, dermatology, metabolic disease, infectious disease, and women’s health. Partnerships among biopharma organizations, diagnostics developers, academic centers, hospitals, and contract manufacturers are becoming essential to translate microbial signatures into clinically validated, reimbursable, and scalable healthcare products.

Cumulative Impact of Artificial Intelligence on Microbiome Innovation

Artificial intelligence is compounding progress by accelerating microbiome data interpretation, strain-function mapping, biomarker discovery, and clinical trial design. Machine learning models help connect microbial abundance, microbial genes, metabolites, host genomics, diet, medications, lifestyle factors, and disease phenotypes in ways that traditional statistical approaches often cannot scale.

The cumulative impact is most visible in target identification, patient stratification, formulation optimization, adverse-event surveillance, and longitudinal response monitoring. AI-enabled platforms can improve study efficiency and signal detection, but adoption still depends on transparent models, validated datasets, reproducible findings, privacy protection, bias control, and clinically meaningful endpoints accepted by regulators, clinicians, and payers.

Key Regional Insights Across the Human Microbiome Market

North America leads in clinical translation, supported by NIH-funded microbiome research, FDA pathways for live biotherapeutic products, advanced sequencing capacity, academic medical centers, and venture-backed biotechnology activity. The region’s emphasis on clinical trials, molecular diagnostics, recurrent C. difficile infection treatment, inflammatory bowel disease research, and oncology-adjacent microbiome studies supports a strong evidence-generation environment.

Europe remains strong in microbiome regulation, nutrition science, biobanking, and clinical research, while European Union rules on health claims and medical products shape evidence-based product positioning. Asia-Pacific is expanding through China, India, Japan, South Korea, and Australia, where sequencing infrastructure, probiotic consumption, functional food innovation, precision medicine programs, and digital health adoption are advancing microbiome applications.

Latin America, led by Brazil and Mexico, is gaining relevance in nutrition, probiotics, gastroenterology, and population-diverse microbiome studies. The Middle East, especially GCC health systems, is investing in genomics, preventive care, and national precision medicine programs that can support microbiome integration. Africa offers underrepresented microbial diversity and important public health research opportunities, particularly for infectious disease, nutrition, maternal health, and environment-linked microbiome studies.

Key Group Insights for Microbiome Growth Strategies

The European Union and G7 economies provide strong foundations for microbiome therapeutics, diagnostics, and nutrition innovation because of advanced clinical infrastructure, high research intensity, mature regulatory systems, and established reimbursement evaluation processes. NATO economies overlap with many leading biomedical markets, supporting cross-border research collaboration, manufacturing resilience, clinical data exchange, antimicrobial resistance research, and health security applications tied to host-microbiome science.

BRICS countries are becoming increasingly important due to large patient populations, expanding sequencing capacity, rising chronic disease burden, and local biomanufacturing ambitions. ASEAN markets show rising demand for gut health products, preventive care, maternal and infant nutrition, and functional foods, while GCC countries are using genomics, digital health, and precision medicine investments to position microbiome science within national health transformation programs.

Key Country Insights Shaping Human Microbiome Demand

The United States remains the anchor market for microbiome therapeutics, clinical trials, sequencing-based diagnostics, and FDA-recognized product pathways, while Canada contributes strong academic research, public health expertise, and regulatory alignment with evidence-based healthcare standards. Mexico and Brazil are important Latin American markets for probiotics, nutrition, gastroenterology, and population-diverse microbiome studies, supported by growing interest in preventive health and diet-linked metabolic conditions.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine clinical research strength with nutrition science, diagnostics, pharmaceutical capabilities, biobanks, and strong hospital networks; Russia maintains scientific capacity and microbiology expertise despite market-access and geopolitical complexity. Germany and France are particularly relevant for regulated healthcare innovation and nutrition research, while the United Kingdom benefits from genomics infrastructure and translational research networks.

China, India, Japan, Australia, and South Korea are accelerating through sequencing investments, digital health adoption, functional food demand, clinical research, and precision medicine initiatives. China’s large-scale genomics capacity, India’s expanding biotechnology base, Japan’s long-standing probiotic and functional food culture, Australia’s clinical research quality, and South Korea’s digital health and biopharma capabilities collectively strengthen Asia-Pacific’s role in human microbiome innovation.

Actionable Recommendations for Human Microbiome Leaders

Industry leaders should prioritize clinically validated indications, differentiated mechanisms of action, and regulatory-ready evidence packages. The strongest strategies combine strain-level characterization, standardized manufacturing, genomic and phenotypic identity testing, safety documentation, stability data, and endpoints that payers, clinicians, and regulators can evaluate.

Firms should also invest in AI-enabled analytics, longitudinal datasets, biobank partnerships, companion diagnostics, and multi-omics platforms while avoiding unsupported wellness claims. Successful commercialization will depend on medical education, reimbursement planning, quality control for live products, cold-chain and storage validation where required, and partnerships that connect discovery, clinical development, manufacturing, regulatory affairs, and market access.

Research Methodology for Human Microbiome Market Intelligence

Research methodology is built from verified secondary research, including regulatory announcements, clinical trial registries, peer-reviewed microbiome literature, public health agency resources, patent activity, product approval records, technical guidelines, and macroeconomic indicators relevant to healthcare, biotechnology, diagnostics, and nutrition.

Insights were triangulated across product type, application, region, end-user demand, clinical maturity, and regulatory readiness. The methodology emphasizes evidence strength, reproducibility, clinical relevance, safety, manufacturing feasibility, and market applicability, with special attention to microbiome therapeutics, diagnostics, probiotics, prebiotics, synbiotics, postbiotics, sequencing, AI analytics, and live biotherapeutic manufacturing.

Conclusion: Evidence-Based Growth in the Human Microbiome Market

The human microbiome market is entering a more disciplined phase in which clinical proof, regulatory clarity, AI-enabled analysis, validated biomarkers, and scalable manufacturing matter more than broad health claims. Approved microbiota-based therapies for recurrent C. difficile infection have strengthened confidence in the field and created a reference point for future live biotherapeutic development.

Future progress will come from evidence-backed therapeutics, precision diagnostics, functional nutrition, and data platforms that translate complex microbial ecosystems into actionable healthcare decisions. Organizations that combine scientific rigor with commercial discipline, transparent data practices, and regulatory preparedness will be best positioned to lead.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Human Microbiome Market, by Type
7.1. Introduction
7.2. Antibiotics
7.3. Diagnostic Devices
7.3.1. Microbiome Sequencing Devices
7.3.2. PCR-Based Diagnostics
7.4. Prebiotics
7.4.1. Inulin
7.4.2. Oligosaccharides
7.5. Probiotics
7.6. Synbiotics
8. Human Microbiome Market, by Target Microbiome Site
8.1. Introduction
8.2. Gut Microbiome
8.3. Nasal & Respiratory Microbiome
8.4. Oral Microbiome
8.5. Skin Microbiome
8.6. Vaginal Microbiome
9. Human Microbiome Market, by Application
9.1. Introduction
9.2. Diagnostics
9.2.1. Biomarker Discovery
9.2.2. Clinical Diagnostics
9.2.3. Companion Diagnostics
9.3. Supplements
9.4. Therapeutics
9.4.1. Gastrointestinal Disorders
9.4.2. Infections
9.4.3. Metabolic Disorders
9.4.4. Skin Disorders
10. Human Microbiome Market, by End User
10.1. Introduction
10.2. Diagnostic Laboratories
10.3. Home Care Settings
10.4. Hospitals & Clinics
10.5. Pharmaceutical & Biotechnology Companies
10.6. Research Institutes
11. Human Microbiome Market, by Region
11.1. Asia-Pacific
11.2. North America
11.3. Latin America
11.4. Europe
11.5. Middle East
11.6. Africa
12. Human Microbiome Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. Human Microbiome Market, by Country
13.1. United States
13.2. China
13.3. Germany
13.4. United Kingdom
13.5. India
13.6. Japan
13.7. Russia
13.8. Brazil
13.9. Canada
13.10. Italy
13.11. Mexico
13.12. France
13.13. Spain
13.14. Australia
13.15. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. AOBiome, LLC
15.2. Astarte Medical
15.3. Axial Therapeutics, Inc.
15.4. Azitra
15.5. BioGaia AB
15.6. BioHM Health Inc.
15.7. BiomeBank
15.8. BiomeSense, Inc.
15.9. BiomX Ltd.
15.10. DuPont de Nemours, Inc.
15.11. Enterome Bioscience
15.12. Exeliom Biosciences SAS
15.13. Ferring B.V.
15.14. Finch Therapeutics Group, Inc.
15.15. Ginkgo Bioworks, Inc.
15.16. Illumina, Inc.
15.17. Infinant Health Inc.
15.18. International Flavors & Fragrances Inc.
15.19. Intralytix, Inc.
15.20. Invivo Healthcare
15.21. MaaT Pharma
15.22. Merck KGaA
15.23. Metabiomics Corporation
15.24. OptiBiotix Health plc
15.25. Osel Inc.
15.26. Pendulum Therapeutics
15.27. Rebiotix Inc.
15.28. Synlogic, Inc.
15.29. Synthetic Biologics, Inc.
15.30. Theriva Biologics, Inc.
15.31. Viome Life Sciences, Inc.
15.32. Yakult Honsha Co., Ltd.
List of Figures
FIGURE 1. GLOBAL HUMAN MICROBIOME MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL HUMAN MICROBIOME MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL HUMAN MICROBIOME MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL HUMAN MICROBIOME MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL HUMAN MICROBIOME MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL HUMAN MICROBIOME MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL HUMAN MICROBIOME MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL HUMAN MICROBIOME MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL HUMAN MICROBIOME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL DIAGNOSTIC DEVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL DIAGNOSTIC DEVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL DIAGNOSTIC DEVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL MICROBIOME SEQUENCING DEVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL MICROBIOME SEQUENCING DEVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL MICROBIOME SEQUENCING DEVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL PCR-BASED DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL PCR-BASED DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL PCR-BASED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PREBIOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PREBIOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PREBIOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL INULIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL INULIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL INULIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL OLIGOSACCHARIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL OLIGOSACCHARIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL OLIGOSACCHARIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PROBIOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PROBIOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PROBIOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL SYNBIOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SYNBIOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SYNBIOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL GUT MICROBIOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL GUT MICROBIOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL GUT MICROBIOME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL NASAL & RESPIRATORY MICROBIOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL NASAL & RESPIRATORY MICROBIOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL NASAL & RESPIRATORY MICROBIOME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL ORAL MICROBIOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL ORAL MICROBIOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL ORAL MICROBIOME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SKIN MICROBIOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SKIN MICROBIOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SKIN MICROBIOME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL VAGINAL MICROBIOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL VAGINAL MICROBIOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL VAGINAL MICROBIOME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL SUPPLEMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL SUPPLEMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL GASTROINTESTINAL DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL GASTROINTESTINAL DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL GASTROINTESTINAL DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL SKIN DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL SKIN DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL SKIN DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 122. EUROPE HUMAN MICROBIOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. EUROPE HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 124. EUROPE HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 125. EUROPE HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 126. EUROPE HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 127. EUROPE HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 128. EUROPE HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 129. EUROPE HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 130. EUROPE HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 131. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 133. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 134. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 140. AFRICA HUMAN MICROBIOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. AFRICA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 142. AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 143. AFRICA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 144. AFRICA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 145. AFRICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 146. AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 147. AFRICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 148. AFRICA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 150. ASEAN HUMAN MICROBIOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. ASEAN HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 152. ASEAN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 153. ASEAN HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 154. ASEAN HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 155. ASEAN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 156. ASEAN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 157. ASEAN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 158. ASEAN HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 159. GCC HUMAN MICROBIOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. GCC HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 161. GCC HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 162. GCC HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 163. GCC HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 164. GCC HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 165. GCC HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 166. GCC HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 167. GCC HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 177. BRICS HUMAN MICROBIOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 178. BRICS HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 179. BRICS HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 180. BRICS HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 181. BRICS HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 182. BRICS HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 183. BRICS HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 184. BRICS HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 185. BRICS HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 186. G7 HUMAN MICROBIOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 187. G7 HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 188. G7 HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 189. G7 HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 190. G7 HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 191. G7 HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 192. G7 HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 193. G7 HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 194. G7 HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 195. NATO HUMAN MICROBIOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 196. NATO HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 197. NATO HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 198. NATO HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 199. NATO HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 200. NATO HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 201. NATO HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 202. NATO HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 203. NATO HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 204. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 205. UNITED STATES HUMAN MICROBIOME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 206. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 207. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 208. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 209. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 210. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 211. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 212. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 213. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 214. CHINA HUMAN MICROBIOME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 215. CHINA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 216. CHINA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 217. CHINA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 218. CHINA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 219. CHINA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 220. CHINA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 221. CHINA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 222. CHINA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. GERMANY HUMAN MICROBIOME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 224. GERMANY HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 225. GERMANY HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 226. GERMANY HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 227. GERMANY HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 228. GERMANY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 229. GERMANY HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 230. GERMANY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 231. GERMANY HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 232. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 233. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 234. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 235. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 236. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 237. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 238. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 239. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 240. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 241. INDIA HUMAN MICROBIOME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 242. INDIA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 243. INDIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 244. INDIA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 245. INDIA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 246. INDIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 247. INDIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 248. INDIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 249. INDIA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 250. JAPAN HUMAN MICROBIOME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 251. JAPAN HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 252. JAPAN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 253. JAPAN HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 254. JAPAN HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 255. JAPAN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 256. JAPAN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 257. JAPAN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 258. JAPAN HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 259. RUSSIA HUMAN MICROBIOME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 260. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 261. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 262. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 263. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 264. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 265. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 266. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 267. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 268. BRAZIL HUMAN MICROBIOME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 269. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 270. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 271. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 272. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 273. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 274. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 275. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 276. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 277. CANADA HUMAN MICROBIOME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 278. CANADA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 279. CANADA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 280. CANADA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 281. CANADA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 282. CANADA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 283. CANADA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 284. CANADA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 285. CANADA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 286. ITALY HUMAN MICROBIOME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 287. ITALY HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 288. ITALY HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 289. ITALY HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 290. ITALY HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 291. ITALY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 292. ITALY HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 293. ITALY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 294. ITALY HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 295. MEXICO HUMAN MICROBIOME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 296. MEXICO HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 297. MEXICO HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 298. MEXICO HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 299. MEXICO HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 300. MEXICO HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 301. MEXICO HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 302. MEXICO HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 303. MEXICO HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 304. FRANCE HUMAN MICROBIOME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 305. FRANCE HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 306. FRANCE HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 307. FRANCE HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 308. FRANCE HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 309. FRANCE HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 310. FRANCE HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 311. FRANCE HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 312. FRANCE HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 313. SPAIN HUMAN MICROBIOME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 314. SPAIN HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 315. SPAIN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 316. SPAIN HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 317. SPAIN HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 318. SPAIN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 319. SPAIN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 320. SPAIN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 321. SPAIN HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 322. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 323. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 324. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 325. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 326. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 327. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 328. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 329. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 330. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 331. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 332. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 333. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2017-2032 (USD MILLION)
TABLE 334. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2017-2032 (USD MILLION)
TABLE 335. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2017-2032 (USD MILLION)
TABLE 336. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 337. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 338. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 339. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 340. GLOBAL HUMAN MICROBIOME MARKET SHARE, BY KEY PLAYER, 2025
TABLE 341. GLOBAL HUMAN MICROBIOME MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • AOBiome, LLC
  • Astarte Medical
  • Axial Therapeutics, Inc.
  • Azitra
  • BioGaia AB
  • BioHM Health Inc.
  • BiomeBank
  • BiomeSense, Inc.
  • BiomX Ltd.
  • DuPont de Nemours, Inc.
  • Enterome Bioscience
  • Exeliom Biosciences SAS
  • Ferring B.V.
  • Finch Therapeutics Group, Inc.
  • Ginkgo Bioworks, Inc.
  • Illumina, Inc.
  • Infinant Health Inc.
  • International Flavors & Fragrances Inc.
  • Intralytix, Inc.
  • Invivo Healthcare
  • MaaT Pharma
  • Merck KGaA
  • Metabiomics Corporation
  • OptiBiotix Health plc
  • Osel Inc.
  • Pendulum Therapeutics
  • Rebiotix Inc.
  • Synlogic, Inc.
  • Synthetic Biologics, Inc.
  • Theriva Biologics, Inc.
  • Viome Life Sciences, Inc.
  • Yakult Honsha Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages181
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.98 Billion
Forecasted Market Value ( USD ) by 2032 $ 11.4 Billion
Compound Annual Growth Rate24.8%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Human Microbiome - Global Strategic Business Report - Product Image

Human Microbiome - Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
Human Microbiome Market (5th Edition): Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Product, Type of Biologic, Route of Administration, Drug Formulation, Target Indication, Target Therapeutic Area and Geographical Regions - Product Image

Human Microbiome Market (5th Edition): Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Product, Type of Biologic, Route of Administration, Drug Formulation, Target Indication, Target Therapeutic Area and Geographical Regions

  • Report
  • 552 Pages
  • Global
From
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031 - Product Image

Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031

  • Report
  • 371 Pages
  • Global
From
Human Microbiome Market Size, Share, Trends and Forecast by Product, Application, Disease Type, and Region, 2026-2034 - Product Image

Human Microbiome Market Size, Share, Trends and Forecast by Product, Application, Disease Type, and Region, 2026-2034

  • Report
  • 150 Pages
  • Global
From
Human Microbiome Market Outlook 2026-2034: Market Share, and Growth Analysis by Product Type, Application, End User, Technology - Product Image

Human Microbiome Market Outlook 2026-2034: Market Share, and Growth Analysis by Product Type, Application, End User, Technology

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.